Tigress Financial Reiterates Buy on Hims & Hers Health, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Tigress Financial analyst Ivan Feinseth reiterated a Buy rating on Hims & Hers Health (NYSE:HIMS) and raised the price target from $12 to $14.
June 15, 2023 | 3:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tigress Financial reiterated a Buy rating on Hims & Hers Health and raised the price target from $12 to $14.
The Buy rating and increased price target by Tigress Financial analyst Ivan Feinseth indicate a positive outlook for Hims & Hers Health. This news is likely to have a positive impact on the stock price in the short term as it reflects the analyst's confidence in the company's growth potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100